Increased Plasminogen Activator Inhibitor Activity in Non Insulin Dependent Diabetic Patients – Relationship with Plasma Insulin

Summary

Type 2 diabetic patients are known to frequently have a high insulin level and were recently described as having high plasminogen activator inhibitor (PAI) activity, compared to normal controls. As we have shown in several clinical conditions (normal subjects, obese patients, angina pectoris patients) that plasma PAI activity was linked with plasma insulin, we have studied in 38 type 2 diabetic patients the relationship between PAI activity, insulin and other parameters. Patients showed higher level of PAI activity, as well as plasma glucose, insulin, triglyceride, cholesterol and Apolipoprotein B levels than normal controls; highest values were observed with diabetic patients also affected by coronary artery disease. A significant correlation was found between PAI activity and insulin (r = 0.60, p <0.001), body mass index (r = 0.32, p <0.05) and Apolipoprotein B (r = 0.33, p <0.05). The two latter correlations disappeared after adjustment for insulin.

These results are in agreement with our previous report showing an in vitro effect of insulin on the synthesis of PAI by a hepatocellular cell line. Hyperinsulinemia presented by type 2 diabetic patients may increase the hepatic synthesis of PAI, inducing an hypofibrinolysis, which could play a role in the development of the vascular complications.

Attempts to reduce hyperinsulinemia could have a favorable effect by lowering PAI activity.

Keywords

Non insulin dependent diabetics - Plasminogen activator inhibitor - Insulin - Triglyceride - Body mass index

• References

• 1 Ostermann H, van de Loo J. Factors of the haemostatic system in diabetic patients. A survey of controlled studies Haemostasis 1986; 16: 386-416
• 2 Fuller JH, Keen H, Jarrett RJ, Omer T, Meade TW, Chakrabarti R, North WR S, Stirling Y. Haemostatic variables associated with diabetes and its complications. Br Med J 1979; 2: 964-966
• 3 Garcia Frade LJ, de la Calle H, Alava I, Navarro JL, Creighton LJ, Gaffney PJ. Diabetes mellitus as a hypercoagulable state. Its relationship with fibrin fragments and vascular damage. Thromb Res 1987; 47: 533-540
• 4 Auwerx J, Bouillon R, Collen D, Geboers J. Tissue-type plasminogen activator inhibitor in diabetes mellitus. Arteriosclerosis 1988; 8: 68-72
• 5 Bachmann F. Fibrinolysis In: Thrombosis and Haemostasis. Ver-straete M, Vermylen J, Lijnen HR, Arnout J. (eds) Leuven University Press; 1987 pp 227-265
• 6 Sprengers ED, Kluft C. Plasminogen activator inhibitors. Blood 1987; 69: 381-387
• 7 Vague P, Juhan-Vague I, Aillaud MF, Badier C, Viard R, Alessi MC, Collen D. Correlation between blood fibrinolytic activity, plasminogen activator inhibitor level, plasma insulin level and relative body weight in normal and obese subjects. Metabolism 1986; 2: 250-253
• 8 Juhan-Vague I, Vague P, Alessi MC, Badier C, Valadier J, Aillaud MF, Atlan C. Relationship between plasma insulin, triglyceride, body mass index, and plasminogen activator inhibitor 1. Diab Metab 1987; 13: 331-336
• 9 Vague P, Juhan-Vague I, Alessi MC, Badier C, Valadier J. Metformin decreases the high plasminogen activator inhibition capacity, plasma insulin and triglyceride levels in non-diabetic obese subjects. Thromb Haemostas 1987; 57: 326-328
• 10 Juhan-Vague I, Alessi MC, Joly P, Thirion X, Vague P, DeClerck PJ, Serradimigni A, Collen D. Plasma plasminogen activator inhibitor 1 in angina pectoris. Influence of plasma insulin and the acute-phase response. Arteriosclerosis (in press);
• 11 Verheijen JH, Chang GT G, Kluft C. Evidence for the occurrence of a fast acting inhibitor for tissue type plasminogen activator in human plasma. Thromb Haemostas 1984; 51: 392-395
• 12 Clauss A. Gerinnungsphysiologische Schnellmethode zur Bestimmung des Fibrinogens. Acta Haematol 1957; 17: 237-246
• 13 Bucolo G, David M. Quantitative determination of serum triglycerides by use of enzymes. Clin Chem 1973; 19: 475-482
• 14 Seidel J. Reagent for the enzymatic determination of serum total cholesterol with improved lipolytic efficiency. Clin Chem 1983; 29 (suppl) 1075-1085
• 15 Warnick GR, Benderson JM, Albers JJ. Quantitation of high density lipoprotein sub classes after separation by dextran sulfate and Mg²⁺precipitation. Clin Chem 1982; 28: 1574
• 16 Kruithof EK O, Nicoloso G, Bachmann F. Plasminogen activator inhibitor 1. Development of a radioimmunoassay and observations on its plasma concentrati. Blood 1987; 70: 1645-1653
• 17 Alessi MC, Juhan-Vague I, Kooistra T, DeClerck P, Collen D. Insulin stimulates the synthesis of plasminogen activator inhibitor 1 by the human hepatocellular cell line Hep G2. Thromb Haemostas 1988; 60: 491-494
• 18 Brommer EP J, Verheijen JH, Chang GT G, Rijken DC. Masking of fibrinolytic response to stimulation by an inhibitor of tissue-type plasminogen activator in plasma. Thromb Haemostas 1984; 52: 154-156
• 19 Ahmad M, Saku K, Glas-Greenwalt P, Kashyap ML. Inhibitor and activator of plasminogen in patients with hyperlipoproteinemias. Thromb Haemostas 1985; 54: 266 (Abstr 1578)
• 20 Juhan-Vague I, Valadier J, Alessi MC, Aillaud MF, Ansaldi J, Philip-Joet C, Holvoet P, Serradimigni A, Collen D. Deficient t-PA release and elevated PA Inhibitor levels in patients with spontaneous or recurrent deep venous thrombosis. Thromb Haemostas 1987; 57: 67-72
• 21 Mehta J, Mehta P, Lawson D, Saldeen T. Plasma tissue plasminogen activator inhibitor levels in coronary artery disease: correlation with age and serum triglyceride concentrations. J Am Coll Cardiol 1987; 9: 263-268
• 22 Meade TW, North WR S, Chakrabarti RR, Stirling Y, Haines AP, Thompson SG, Brozovic M. Haemostatic function and cardiovascular death: early results of a prospective study. Lancet 1980; 1: 1050-1054
• 23 Meade TW. The epidemiology of haemostatic and other variables in coronary artery disease. In: Thrombosis and Haemostasis. Verstrate M, Vermylen J, Lijnen HR, Arnout J. (eds) Leuven University Press; Leuven: 1987. pp 37-60
• 24 Juhan-Vague I, Aillaud MF, De Cock F, Philip-Joet C, Arnaud C, Serradimigni A, Collen D. The fast-acting inhibitor of tissue-type plasminogen activator is an acute phase reactant protein. In: Progress in Fibrinolysis, Vol. VII. Davidson JF, Donati MB, Coccheri S. (eds) Churchill Livingstone; Edinburgh: 1985. pp 146-149
• 25 Aillaud MF, Juhan-Vague I, Alessi MC, Marecal M, Vinson MF, Arnaud C, Vague P, Collen D. Increased plasminogen activator inhibitor (PAI) levels in the post-operative period. No cause-effect relation with increased cortisol. Thromb Haemostas 1985; 54: 466-468
• 26 Kluft C, Verheijen JH, Jie AF H, Rijken DC, Preston FE, Sue-Ling HM, Jespersen J, Aasen AO. The postoperative fibrinolytic shutdown: a rapidly reverting acute phase pattern for the fast-acting inhibitor of tissue-type plasminogen activator after trauma. Scand J Clin Lab Invest 1985; 45: 605-610
• 27 Aillaud MF, Pignol F, Alessi MC, Harle JR, Escande M, Mongin M, Juhan-Vague I. Increase in plasma concentration of plasminogen activator inhibitor, fibrinogen, von Willebrand factor, FVIII: C and in erythrocyte sedimentation rate with age. Thromb Haemostas 1986; 55: 330-332
• 28 Hamsten A, Wiman B, De Faire K, Blombäck M. Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction. N Engl J Med 1985; 313: 1557-1563
• 29 Hamsten A, Walldius G, Szamosi A, Blombäck M, De Faire U, Dahlen G, Landon C, Wiman B. Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction. Lancet 1987; 2: 3-8
• 30 Stout RW, Vallance-Owen J. Insulin and atheroma. Lancet 1979; 1: 1078-1080
• 31 Pyorala K. Relationship of glucose tolerance and plasma insulin to the incidence of coronary heart disease. Results from two population studies in Finland Diabetes Care 1979; 2: 131-141
• 32 Ducimetiere P, Eschwege E, Papoz L, Richard JL, Claude JR, Rosselin G. Relationship of plasma insulin levels to the incidence of myocardial infarction and coronary heart disease mortality in a middle-aged population. Diabetologia 1980; 19: 205-210
• 33 Welbom TA, Weame K. Coronary heart disease incidence and cardiovascular mortality in Busselton with reference to glucose and insulin concentrations. Diabetes Care 1979; 2: 154-160
• 34 Collen D, Juhan-Vague I. Fibrinolysis and atherosclerosis. Semin Thromb Haemostas 1988; 14: 180-183